During the past decade, Kresge Eye Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 8 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kresge Eye Institute" #1 sponsor was "Pfizer" with 4 trials, followed by "Glaukos Corporation" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Kresge Eye Institute" with 2 trials sponsored and "ThromboGenics" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kresge Eye Institute" #1 collaborator was "Alcon Research" with 1 trials as a collaborator, "Allergan" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Eye Institute (NEI)" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Kresge Eye Institute" are "Geographic Atrophy" (3 trials), "Diabetic Macular Edema" (2 trials), "Advanced Malignancies Except Leukemia" (1 trials), "Age Related Macular Degeneration" (1 trials) and "Age-Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Kresge Eye Institute" in a lesser frequency.

Most popular intervention types in "Kresge Eye Institute" are "Drug" (19 trials), "Other" (3 trials), "Procedure" (3 trials), "Device" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lampalizumab" (2 trials), "125 µg Ocriplasmin" (1 trials), "1mg triamcinolone acetonide" (1 trials), "4mg triamcinolone acetonide" (1 trials) and "ACU-4429" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kresge Eye Institute" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kresge Eye Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Kresge Eye Institute, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kresge Eye Institute, 3 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".